Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
January 09 2017 - 8:01AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announced that GlaxoSmithKline plc
(NYSE:GSK) (LSE:GSK) has nominated a second target, PRAME
(preferentially expressed antigen in melanoma), under the strategic
collaboration and licensing agreement between the companies.
Adaptimmune will be responsible for PRAME preclinical TCR
development and delivery of the IND package to GSK. The nomination
of a second target meets a milestone set forth in the agreement.
Adaptimmune and GSK initially announced their strategic
collaboration and licensing agreement in June 2014 for up to five
programs, the first being the NY-ESO SPEAR® T-cell therapy program,
and the agreement was subsequently expanded in February 2016 to
accelerate development of Adaptimmune’s NY-ESO SPEAR T-cell therapy
toward registration trials in synovial sarcoma. Following the
nomination of PRAME as a second target, Adaptimmune will take the
program through preclinical testing to IND. GSK retains the right
to nominate up to three additional targets, if GSK exercises its
option on NY-ESO; however, this excludes targets on which work is
already under way, including Adaptimmune’s proprietary MAGE-A10,
MAGE-A4 and AFP programs.
“The nomination of this next target marks an important step
forward for the collaboration,” commented Helen Tayton-Martin,
Adaptimmune’s Chief Operating Officer and responsible for the
alliance. “The early clinical results we have seen in synovial
sarcoma with our SPEAR T-cell therapy targeting NY-ESO-1, the first
target nominated by GSK, have been promising thus far, and we are
accelerating that program toward registration studies. The
nomination of PRAME as GSK’s second target is further validation of
our technology, and our goal is to deliver this IND package as
expeditiously as possible.”
Under the terms of the agreement, the potential development
milestones Adaptimmune is eligible to receive solely in relation to
the PRAME program could amount to approximately $300 million, if
GSK exercises its option and successfully develops this target in
more than one indication and more than one Human Leukocyte Antigen
(HLA) type. Adaptimmune would also receive tiered sales milestones
and mid-single to low double-digit royalties on worldwide net
sales.
About AdaptimmuneAdaptimmune is a clinical
stage biopharmaceutical company focused on novel cancer
immunotherapy products based on its SPEAR (Specific Peptide
Enhanced Affinity Receptor) T-cell platform. Established in 2008,
the Company aims to utilize the body’s own machinery - the T-cell -
to target and destroy cancer cells by using engineered, increased
affinity TCRs as a means of strengthening natural patient T-cell
responses. Adaptimmune’s lead program is a SPEAR T-cell therapy
targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell
therapy has demonstrated signs of efficacy and tolerability in
Phase 1/2 trials in solid tumors and in hematologic cancer types,
including synovial sarcoma and multiple myeloma. Adaptimmune has a
strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the
NY-ESO TCR program. In addition, Adaptimmune has a number of
proprietary programs. These include SPEAR T-cell therapies
targeting the MAGE-A10, AFP, and MAGE-A4 cancer antigens, which all
have open INDs. The Company has identified over 25 intracellular
target peptides preferentially expressed in cancer cells and is
currently progressing 12 through unpartnered research programs.
Adaptimmune has over 250 employees and is located in Oxfordshire,
U.K. and Philadelphia, USA. For more information:
http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on November 10, 2016, and our other SEC filings. The
forward-looking statements contained in this press release speak
only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements
to reflect subsequent events or circumstances.
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts@adaptimmune.com
Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024